We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Shares of Novavax Inc. NVAX slid 3.46% to $9.22 Friday, on what proved to be an all-around rough trading session for the ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $9.55 which represents a slight increase of $0.72 or 8.15% from the prior close of $8.83. The stock opened at $8.82 and touched a low of ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna ...

Bullish option flow detected in Novavax (NVAX) with 15,743 calls trading, 1.7x expected, and implied vol increasing over 2 points to 73.97%.

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.

In the latest trading session, Novavax (NVAX) closed at $8.55, marking a +0.53% move from the previous day. The first human bird flu death in the US has Moderna's vaccine development in focus for ...

Novavax (NVAX) ended the recent trading session at $8.55, demonstrating a +0.53% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.83%.